AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29265090 — intervention group
Group type: COMPARATOR
Intervention: NSAID monotherapy
Number of subjects: 239
Study 25453481 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose exercise regimen
Number of subjects: 39
Study 25453481 — intervention group
Group type: COMPARATOR
Intervention: Low dose exercise regimen
Number of subjects: 39
Study 25453481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise groups
Number of subjects: 39
Study 24428754 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily for 7 days
Number of subjects: 54
Study 24428754 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg daily for 7 days
Number of subjects: 54
Study 24428754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both clopidogrel and prasugrel
Number of subjects: 54
Study 18637782 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of enteric-coated aspirin tablets daily
Number of subjects: 209
Study 18637782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 15060224 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management (MedMgt)
Number of subjects: 540
Study 15060224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Comb)
Number of subjects: 540
Study 15060224 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification therapy (Beh)
Number of subjects: 540
Study 15060224 — intervention group
Group type: COMPARATOR
Intervention: Usual community comparison (CC)
Number of subjects: 540
Study 11753057 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection with rehabilitation
Number of subjects: 39
Study 11753057 — intervention group
Group type: COMPARATOR
Intervention: Sham injection with rehabilitation
Number of subjects: 39
Study 8997805 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-relaxation
Number of subjects: 40
Study 8997805 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 8480506 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0.0010, 0.0020, 0.0040, 0.0080 mg.kg‐1; total 0.0150 mg.kg‐1)
Number of subjects: 19
Study 8480506 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (0.0125, 0.0250, 0.0500, 0.1000 mg.kg‐1; total 0.1875 mg.kg‐1)
Number of subjects: 19
Study 3321926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram alphacalcidol
Number of subjects: 29
Study 3321926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11376175 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 units, 40 units/site at five lumbar paravertebral levels)
Number of subjects: 31
Study 11376175 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 31
Study 31300167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 0
Study 30052211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative transesophageal echocardiography (TEE)
Number of subjects: 80
Study 30052211 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 80
Study 26885528 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) plus B Complex (B1/B12)
Number of subjects: 270
Study 26885528 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (PGB)
Number of subjects: 270
Study 24310050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N₂O) anesthesia
Number of subjects: 442
Study 24310050 — intervention group
Group type: COMPARATOR
Intervention: No nitrous oxide (N₂O) anesthesia
Number of subjects: 442
Study 22367114 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (15 mg, t.i.d. for 4 weeks)
Number of subjects: 146
Study 22367114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (t.i.d. for 4 weeks)
Number of subjects: 146
Study 20162245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose dobutamine infusion
Number of subjects: 89
Study 20162245 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 89
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon (melatonin receptor agonist)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine and nonbenzodiazepine sedative-hypnotic agents
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedating antihistamines
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (herbal preparation)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian (herbal preparation)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (nonpharmacologic option)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (nonpharmacologic option)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene education (nonpharmacologic option)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (nonpharmacologic option)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical intention (nonpharmacologic option)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (nonpharmacologic option)
Number of subjects: 0
Study 17192164 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control (nonpharmacologic option)
Number of subjects: 0
Study 15589562 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 329
Study 15589562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 12404219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg 3 times daily) for 5 days
Number of subjects: 28
Study 12404219 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 28
Study 12404219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (5 days)
Number of subjects: 28
Study 10622992 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced emergency department referral to primary care
Number of subjects: 189
Study 10622992 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study 7772423 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 73
Study 7772423 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 73
Study 7772423 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal outcomes
Number of subjects: 73
Study 2186494 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2‐interferon (alpha 2‐IF)
Number of subjects: 412
Study 286280 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined footrest
Number of subjects: 0
Study 286280 — intervention group
Group type: COMPARATOR
Intervention: Conventional panoramic technique without inclined footrest
Number of subjects: 0
Study 31629373 — intervention group
Group type: EXPERIMENTAL
Intervention: Active thermography + standard foot care
Number of subjects: 110
Study 31629373 — intervention group
Group type: COMPARATOR
Intervention: Blinded thermography + standard foot care
Number of subjects: 110
Study 31499384 — intervention group
Group type: EXPERIMENTAL
Intervention: Active supportive care (ASC) + oral erlotinib
Number of subjects: 527
Study 31499384 — intervention group
Group type: COMPARATOR
Intervention: Active supportive care (ASC) only
Number of subjects: 527
Study 31499384 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG 0-1
Number of subjects: 527
Study 31499384 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG 2-3
Number of subjects: 527
Study 31499384 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 75 years
Number of subjects: 527
Study 31499384 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV
Number of subjects: 527
Study 31499384 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 527
Study 27854142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC+)
Number of subjects: 69
Study 27854142 — intervention group
Group type: COMPARATOR
Intervention: No Mitomycin C (MMC‐)
Number of subjects: 69
Study 25913109 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9)-THC at .015 mg/kg
Number of subjects: 24
Study 25913109 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9)-THC at .03 mg/kg
Number of subjects: 24
Study 25913109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25913109 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9)-THC (both doses)
Number of subjects: 24
Study 23329342 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation
Number of subjects: 104
Study 23329342 — intervention group
Group type: COMPARATOR
Intervention: Feeding mother stimulation
Number of subjects: 104
Study 20610478 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE‐choroid sheet transplantation (group 1)
Number of subjects: 14
Study 20610478 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE cell‐suspension transplantation (group 2)
Number of subjects: 14
Study 19283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 12
Study 19283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 12
Study 19283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 12
Study 19283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 12
Study 19283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 12
Study 19283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Other anticonvulsants
Number of subjects: 12
Study 17760538 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRF‐E group (semilunar coronally repositioned flap with EDTA application)
Number of subjects: 15
Study 17760538 — intervention group
Group type: COMPARATOR
Intervention: SCRF group (semilunar coronally repositioned flap without EDTA application)
Number of subjects: 15
Study 15061348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure with cognitive restructuring
Number of subjects: 75
Study 15061348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure without cognitive restructuring
Number of subjects: 75
Study 15061348 — intervention group
Group type: EXPERIMENTAL
Intervention: Community therapists
Number of subjects: 75
Study 15061348 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral treatment experts
Number of subjects: 75
Study 11210393 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniporide (2.5 to 100 mg, administered intravenously)
Number of subjects: 0
Study 9744152 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mibefradil
Number of subjects: 618
Study 9744152 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mibefradil
Number of subjects: 618
Study 9744152 — intervention group
Group type: COMPARATOR
Intervention: mibefradil
Number of subjects: 618
Study 7800183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory setting with constant tidal volume (VC = 8 ml.kg‐1) and varying respiratory frequencies (f = 10, 12, and 14 breaths.min‐1)
Number of subjects: 28
Study 7800183 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant ventilation (112 ml.kg‐1) with modified VC and f
Number of subjects: 28
Study 7800183 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory volume set to achieve an end-tidal PCO2 (PETCO2) of about 35 mmHg
Number of subjects: 28
Study 7800183 — intervention group
Group type: EXPERIMENTAL
Intervention: General surgery (not directly relevant to the measures)
Number of subjects: 28
Study 3288029 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil alone
Number of subjects: 17
Study 3288029 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil and colestipol
Number of subjects: 17
Study 3288029 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil and lovastatin
Number of subjects: 17
Study 29315699 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (30 mg ml-1, 25 μl) as a 0.75 mg single dose (Cohort 1)
Number of subjects: 48
Study 29315699 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (0.75 mg twice daily for 14 days, Cohort 2)
Number of subjects: 48
Study 29315699 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (0.75 mg thrice daily for 14 days, Cohort 3)
Number of subjects: 48
Study 29315699 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (1.5 mg thrice daily unilaterally for 3 days, then bilaterally for up to 14 days, Cohort 4)
Number of subjects: 48
Study 29315699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29315699 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (0.75 mg)
Number of subjects: 48
Study 29315699 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic safety evaluations
Number of subjects: 48
Study 29315699 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib eye drops (up to 30 mg ml-1 tid)
Number of subjects: 48
Study 28801429 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication combined with pepsinogen testing
Number of subjects: 30000
Study 28801429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30000
Study 26170291 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control
Number of subjects: 292
Study 24122883 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 0
Study 24122883 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 0
Study 21392707 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 0
Study 21392707 — intervention group
Group type: COMPARATOR
Intervention: Right internal thoracic artery
Number of subjects: 0
Study 21392707 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft
Number of subjects: 0
Study 18049099 — intervention group
Group type: EXPERIMENTAL
Intervention: 370 MBq of 188Re‐labelled nimotuzumab
Number of subjects: 9
Study 18049099 — intervention group
Group type: EXPERIMENTAL
Intervention: 555 MBq of 188Re‐labelled nimotuzumab
Number of subjects: 9
Study 16773342 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol (group 4)
Number of subjects: 103
Study 16773342 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol under induction with sevoflurane (group 3)
Number of subjects: 103
Study 16773342 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-nitrous oxide/oxygen (group 1)
Number of subjects: 103
Study 16773342 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-air/alfentanil (group 2)
Number of subjects: 103
Study 12577163 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of tramadol (20 mg/ml) and dipyrone (200 mg/ml)
Number of subjects: 191
Study 12577163 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA) with tramadol (20 mg/ml) and dipyrone (200 mg/ml)
Number of subjects: 191
Study 12577163 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of tramadol and dipyrone
Number of subjects: 191
Study 12577163 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA) with tramadol and dipyrone
Number of subjects: 191
Study 10858338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir at a dose of 500 or 750 mg three times a day
Number of subjects: 174
Study 10858338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir with concomitant fluconazole therapy
Number of subjects: 174
Study 10858338 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir without fluconazole therapy
Number of subjects: 174
Study 9337501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 155
Study 9337501 — intervention group
Group type: COMPARATOR
Intervention: Usual juvenile justice services
Number of subjects: 155
Study 1279570 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 8
Study 4030048 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (opiate antagonist)
Number of subjects: 0
Study 31512741 — intervention group
Group type: EXPERIMENTAL
Intervention: Body and movement oriented intervention
Number of subjects: 0
Study 31512741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28249801 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact loading + resistance training (ILRT)
Number of subjects: 163
Study 28249801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic + resistance training (ART)
Number of subjects: 163
Study 28249801 — intervention group
Group type: COMPARATOR
Intervention: Usual care/delayed exercise (DEL)
Number of subjects: 163
Study 25433511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 76
Study 25433511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23569175 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (GLA)
Number of subjects: 104
Study 23569175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite 1 (M1)
Number of subjects: 104
Study 23569175 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 104
Study 21185145 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium heated humidifier (HH) setting
Number of subjects: 23
Study 21185145 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum heated humidifier (HH) setting
Number of subjects: 23
Study 21185145 — intervention group
Group type: COMPARATOR
Intervention: Bench study with no HH, HH at medium setting, and HH at maximum setting
Number of subjects: 23
Study 19473225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate supplementation (500 mg three times daily)
Number of subjects: 43
Study 19473225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 17899046 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐9044 (0.25 mg, 0.5 mg, 1.2 mg, 2.5 mg, 5.0 mg)
Number of subjects: 45
Study 17899046 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐9044 (0.5 mg)
Number of subjects: 45
Study 17899046 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐9044 (1.2 mg)
Number of subjects: 45
Study 17899046 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐9044 (highest two doses)
Number of subjects: 45
Study 17899046 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐9044
Number of subjects: 45
Study 15602801 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced evening light (approximately 265 lux)
Number of subjects: 47
Study 15602801 — intervention group
Group type: COMPARATOR
Intervention: Placebo dim light (approximately 2 lux)
Number of subjects: 47
Study 10566581 — intervention group
Group type: EXPERIMENTAL
Intervention: Weinstein Enhanced Sensory Test (WEST)
Number of subjects: 153
Study 10566581 — intervention group
Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament (SWM) test
Number of subjects: 153
Study 10566581 — intervention group
Group type: EXPERIMENTAL
Intervention: Disk-Criminator test
Number of subjects: 153
Study 10566581 — intervention group
Group type: EXPERIMENTAL
Intervention: Strauch's ten test
Number of subjects: 153
Study 8877724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide 300 mg/m2 on day -3
Number of subjects: 0
Study 8877724 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide 50 mg daily from days -14 to -3
Number of subjects: 0
Study 8877724 — intervention group
Group type: COMPARATOR
Intervention: No cyclophosphamide
Number of subjects: 0
Study 1987817 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 144
Study 6313025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 microgram kg‐1
Number of subjects: 20
Study 6313025 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate 10 microgram kg‐1
Number of subjects: 20
Study 3972647 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Dusodril)
Number of subjects: 100
Study 3972647 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (Dextran, Diazepam, and Vitamins)
Number of subjects: 100
Study 30572526 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (received a 3-hour training session)
Number of subjects: 27
Study 30572526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 27
Study 30572526 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 27
Study 30572526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 27356642 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated intermittent boluses of 10 ml of 0.2% ropivacaine every 60 mins for 48 hours
Number of subjects: 60
Study 27356642 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 10 ml/h of 0.2% ropivacaine for 48 hours
Number of subjects: 60
Study 24751920 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin therapy
Number of subjects: 2993
Study 22850709 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex membrane implant
Number of subjects: 107
Study 22850709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sylastic® membrane implant
Number of subjects: 107
Study 22850709 — intervention group
Group type: COMPARATOR
Intervention: Control group with no transitory implant
Number of subjects: 107
Study 20406960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime physical activity (highest tertile)
Number of subjects: 915
Study 20406960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime physical activity (moderate intensity)
Number of subjects: 915
Study 20406960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime physical activity (greater than median)
Number of subjects: 915
Study 20406960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime physical activity (obese and overweight women)
Number of subjects: 915
Study 18275580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 200